› 4n1z

X-ray diffraction
2.35Å resolution

Crystal Structure of Human Farnesyl Diphosphate Synthase in Complex with BPH-1222

Released:
DOI: 10.2210/pdb4n1z/pdb
PDB entry 4n1z coloured by chain, front view.
PDB entry 4n1z coloured by chain, side view.
PDB entry 4n1z coloured by chain, top view.
Source organism: Homo sapiens
Primary publication:
A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin.
Xia Y, Liu YL, Xie Y, Zhu W, Guerra F, Shen S, Yeddula N, Fischer W, Low W, Zhou X, Zhang Y, Oldfield E, Verma IM
Sci Transl Med 6 263ra161 (2014)
PMID: 25411474

Function and Biology Details

Reactions catalysed: 
Prenyl diphosphate + isopentenyl diphosphate = diphosphate + geranyl diphosphate
Geranyl diphosphate + isopentenyl diphosphate = diphosphate + (2E,6E)-farnesyl diphosphate
Biochemical function:
Biological process:
Cellular component:
  • not assigned
Sequence domains:

Structure analysis Details

Assembly composition:
homo dimer (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-146902 (preferred)
Entry contents:
1 distinct polypeptide molecule
Macromolecule:
Farnesyl pyrophosphate synthase Chain: F
Molecule details ›
Chain: F
Length: 348 amino acids
Theoretical weight: 40.03 KDa
Source organism: Homo sapiens
Expression system: Escherichia coli
UniProt:
  • Canonical: P14324 (Residues: 72-419; Coverage: 83%)
Gene names: FDPS, FPS, KIAA1293
Sequence domains: Polyprenyl synthetase
Structure domains: Farnesyl Diphosphate Synthase

Ligands and Environments

3 bound ligands:
Ligand PO4 2 x PO4
Ligand MG 3 x MG
Ligand N1Z 1 x N1Z
No modified residues

Experiments and Validation Details

Entry percentile scores
X-ray source: APS BEAMLINE 21-ID-G
Spacegroup: P41212
Unit cell:
a: 111.946Å b: 111.946Å c: 67.284Å
α: 90° β: 90° γ: 90°
R-values:
R R work R free
0.206 0.203 0.265
Expression system: Escherichia coli

Quick links

Citations

8 review citations

Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer.
Liu et al. (2017)
7 more

1 mention without citation

A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin.
Xia et al. (2014)